Hansoh Pharmaceutical Group Company Limited

As of December 31, 2025, Hansoh Pharmaceutical Group Company Limited carries a market capitalization of 218.43B, placing it among publicly traded companies globally. Its enterprise value stands at 183.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hansoh Pharmaceutical Group Company Limited's next confirmed earnings release is scheduled for March 30, 2027.

As of December 31, 2025, Hansoh Pharmaceutical Group Company Limited has 6.05B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Hansoh Pharmaceutical Group Company Limited maintains a current ratio of 8.09, meaning it holds 8.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Hansoh Pharmaceutical Group Company Limited's stock has declined approximately 8.92% over the past 52 weeks. The 50-day moving average sits at 33.77, while the 200-day moving average is 34.58.

As of December 31, 2025, Hansoh Pharmaceutical Group Company Limited holds 35.13B in cash and equivalents against 116.96M in total debt, resulting in a net debt position of -35.07B. Total book value stands at 39.36B, with working capital of 34.68B providing operational flexibility.